Skip to main content

Advertisement

Table 2 Baseline and End of Study Acylcarnitines in Controls and Cases

From: Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study

  Baseline p+ End of the Study p+ A vs C B vs D
  Control (A) n = 15 Case (B) n = 17   Control (C) n = 15 Case (D) n = 17    
C0 30.20 (24.80–34.31) 30.40 (28.21–35.58) 0.42 30.10 (24.23–34.74) 29.40 (25.12–31.69) 0.61 0.20 0.0008*
C2 8.23 (6.02–9.94) 7.21 (5.61–11.98) 0.94 6.78 (5.77–9.79) 6.89 (5.47–10.29) 0.95 0.22 0.24
C3 0.65 (0.54–0.82) 0.61 (0.49–0.74) 0.60 0.77 (0.64–0.93) 0.68 (0.50–0.84) 0.18 0.006* 0.35
C3DC 0.08 (0.07–0.10) 0.06 (0.04–0.08) 0.01* 0.08 (0.05–0.09) 0.06 (0.04–0.11) 0.89 0.38 0.32
C4 0.19 (0.14–0.20) 0.11 (0.07–0.16) 0.02* 0.18 (0.12–0.24) 0.13 (0.10–0.16) 0.10 0.27 0.48
C4DC 0.41 (0.25–0.56) 0.45 (0.33–0.53) 0.68 0.41 (0.30–0.53) 0.50 (0.33–0.54) 0.71 0.27 0.74
C5 0.14 (0.12–0.18) 0.12 (0.10–0.15) 0.77 0.16 (0.14–0.20) 0.19 (0.15–0.24) 0.06 0.63 0.050*
C5OH 0.20 (0.13–0.29) 0.25 (0.18–0.28) 0.48 0.22 (0.14–0.24) 0.24 (0.18–0.27) 0.29 0.59 0.96
C5:1 0.03 (0.02–0.4) 0.03 (0.02–0.5) 0.89 0.03 (0.02–0.06) 0.03 (0.02–0.05) 1.00 0.90 0.78
C5DC 0.09 (0.04–0.19) 0.09 (0.05–0.12) 0.40 0.08 (0.06–0.10) 0.08 (0.06–0.10) 0.18 0.48 0.14
C6 0.07 (0.04–0.09) 0.05 (0.04–0.08) 0.79 0.04 (0.03–0.08) 0.05 (0.03–0.07) 0.74 0.20 0.82
C6DC 0.07 (0.04–0.10) 0.06 (0.05–0.08) 0.25 0.06 (0.03–0.08) 0.06 (0.03–0.07) 0.82 0.22 0.78
C8 0.11 (0.07–0.14) 0.06 (0.04–0.07) 0.006* 0.09 (0.07–0.12) 0.10 (0.07–0.12) 0.79 0.20 0.039*
C10 0.07 (0.05–0.10) 0.07 (0.04–0.12) 0.71 0.06 (0.01–0.10) 0.05 (0.02–0.09) 0.04* 0.65 0.09
C10:1 0.09 (0.06–0.13) 0.08 (0.05–0.10) 0.34 0.07 (0.03–0.11) 0.08 (0.07–0.13) 0.41 0.15 0.61
C10:2 0.06 (0.01–0.10) 0.05 (0.02–0.09) 0.74 0.05 (0.03–0.10) 0.07 (0.03–0.10) 0.86 0.71 0.15
C12 0.07 (0.04–0.11) 0.07 (0.05–0.09) 0.66 0.07 (0.04–0.14) 0.08 (0.05–0.09) 0.61 0.38 0.30
C14 0.06 (0.04–0.09) 0.06 (0.05–0.08) 0.69 0.06 (0.04–0.10) 0.05 (0.05–0.09) 0.49 0.30 0.005*
C14:1 0.07 (0.02–0.10) 0.06 (0.05–0.08) 0.55 0.06 (0.05–0.09) 0.05 (0.04–0.10) 0.67 0.89 0.78
C14:2 0.03 (0.03–0.06) 0.04 (0.02–0.07) 0.49 0.05 (0.03–0.07) 0.03 (0.02–0.05) 0.12 0.30 0.17
C16 0.67 (0.52–0.67) 0.60 (0.50–0.73) 0.47 0.57 (0.45–0.68) 0.59 (0.50–0.68) 0.79 0.27 0.57
C160H 0.04 (0.02–0.05) 0.03 (0.03–0.05) 0.58 0.07 (0.04–0.09) 0.04 (0.02–0.05) 0.74 0.04* 0.37
C16:1 0.07 (0.06–0.10) 0.06 (0.03–0.08) 0.10 0.06 (0.05–0.07) 0.05 (0.04–0.07) 0.79 0.06 0.99
C16:1 OH 0.08 (0.06–0.09) 0.09 (0.07–0.11) 0.26 0.07 (0.04–0.09) 0.07 (0.05–0.10) 0.49 0.42 0.35
C18 0.37 (0.32–0.41) 0.31 (0.27–0.45) 0.24 0.36 (0.28–0.45) 0.28 (0.22–0.32) 0.27 0.80 0.03*
C18 OH 0.06 (0.03–0.10) 0.04 (0.03–0.08) 0.66 0.07 (0.03–0.11) 0.05 (0.03–0.11) 0.86 0.38 0.48
C18:1 0.64 (0.59–0.81) 0.74 (0.68–0.84) 0.13 0.64 (0.53–0.79) 0.73 (0.61–0.83) 0.24 0.76 0.92
C18:1 OH 0.03 (0.02–0.03) 0.02 (0.02–0.03) 0.42 0.02 (0.02–0.03) 0.02 (0.02–0.03) 0.95 0.84 0.43
C18:2 0.22 (0.18–0.33) 0.28 (0.22–0.32) 0.36 0.24 (0.21–0.28) 0.22 (0.17–0.30) 0.31 0.97 0.12
  1. ^All values are in μmol/l. Results are reported in Median and Confidence Interval 95%.
  2. +p Values were calculated by Mann–Whitney Test.
  3. p Values were calculated by Wilcoxon Rank Test.
  4. * Significant Result p < 0.05.